MX2010004361A - Metodos para inhibir infeccion viral. - Google Patents

Metodos para inhibir infeccion viral.

Info

Publication number
MX2010004361A
MX2010004361A MX2010004361A MX2010004361A MX2010004361A MX 2010004361 A MX2010004361 A MX 2010004361A MX 2010004361 A MX2010004361 A MX 2010004361A MX 2010004361 A MX2010004361 A MX 2010004361A MX 2010004361 A MX2010004361 A MX 2010004361A
Authority
MX
Mexico
Prior art keywords
viral infection
compounds
methods
inhibiting viral
inhibiting
Prior art date
Application number
MX2010004361A
Other languages
English (en)
Inventor
Michael Kinch
Michael Goldblatt
Original Assignee
Functional Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Functional Genetics Inc filed Critical Functional Genetics Inc
Publication of MX2010004361A publication Critical patent/MX2010004361A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un método para inhibir infección viral en un mamífero en necesidad del mismo, el cual incluye administrar una cantidad efectiva de por lo menos uno de los compuestos FGI-103 los cuales son representados por 273, 365 y 510 ya sea profilácticamente para evitar infección viral, o terapéuticamente después de la infección viral. Estos compuestos parecen inhibir selectivamente la Caspasa 8 como un método para evitar la liberación de la partícula viral infectiva. Ellos pueden ser administrados IV, IP, oralmente o por medio de otras rutas de administración convencionales. Los compuestos son altamente efectivos, requiere de dosis relativamente bajas en el orden 1 ng/kg - 200 mg/kg de peso corporal.
MX2010004361A 2007-10-24 2008-10-23 Metodos para inhibir infeccion viral. MX2010004361A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98222707P 2007-10-24 2007-10-24
PCT/US2008/080867 WO2009055524A1 (en) 2007-10-24 2008-10-23 Methods of inhibiting viral infection

Publications (1)

Publication Number Publication Date
MX2010004361A true MX2010004361A (es) 2010-09-10

Family

ID=40579993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004361A MX2010004361A (es) 2007-10-24 2008-10-23 Metodos para inhibir infeccion viral.

Country Status (12)

Country Link
US (1) US8207209B2 (es)
EP (1) EP2207801B1 (es)
JP (1) JP2011500830A (es)
CN (1) CN101952310A (es)
AU (1) AU2008316890A1 (es)
BR (1) BRPI0818844A2 (es)
CA (1) CA2702248A1 (es)
IL (1) IL205035A0 (es)
MX (1) MX2010004361A (es)
RU (1) RU2010120686A (es)
WO (1) WO2009055524A1 (es)
ZA (1) ZA201002549B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152343A1 (en) * 2009-12-22 2011-06-23 Functional Genetics, Inc. Protease inhibitors and broad-spectrum antiviral
WO2013063462A2 (en) * 2011-10-26 2013-05-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating hcv infection with a small molecule chk2 inhibitor
JPWO2013069780A1 (ja) * 2011-11-11 2015-04-02 出光興産株式会社 ウイルス感染防除剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
JP3457694B2 (ja) * 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US6815461B1 (en) * 1994-01-20 2004-11-09 The University Of North Carolina At Chapel Hill Method of inhibiting retroviral integrase
CA2236168C (en) 1995-11-16 2010-03-23 The Board Of Trustees Of The Leland Stanford Junior University Disruption of expression of multiple alleles of mammalian genes
US6916917B1 (en) * 1998-11-17 2005-07-12 California Institute Of Technology Chimeric pro-caspases and methods of using same
AU1450401A (en) * 1999-11-01 2001-05-14 Auburn University Methods and formulations for the treatment of infectious bursal disease in avian subjects
AU2003219900A1 (en) 2002-02-22 2003-09-09 James R. Eshleman Antigene locks and therapeutic uses thereof
WO2004031209A2 (en) 2002-10-01 2004-04-15 Functional Genetics, Inc. Anti-tsg101 antibodies and their uses for treatment of viral infections
CN1914188A (zh) * 2003-12-05 2007-02-14 北卡罗来纳大学查珀尔希尔分校 用作抗微生物剂的阳离子取代的苯并呋喃
WO2006004608A1 (en) * 2004-06-25 2006-01-12 Functional Genetics, Inc. Compounds, pharmaceutical compositions and methods for inhibiting hiv infectivity
AU2006345003A1 (en) * 2005-08-12 2008-04-10 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
WO2008089125A2 (en) 2007-01-15 2008-07-24 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases Antiviral compounds and methods of using thereof

Also Published As

Publication number Publication date
US8207209B2 (en) 2012-06-26
RU2010120686A (ru) 2011-11-27
ZA201002549B (en) 2011-06-29
BRPI0818844A2 (pt) 2015-04-22
AU2008316890A1 (en) 2009-04-30
JP2011500830A (ja) 2011-01-06
CA2702248A1 (en) 2009-04-30
CN101952310A (zh) 2011-01-19
IL205035A0 (en) 2010-11-30
EP2207801A4 (en) 2011-03-23
WO2009055524A1 (en) 2009-04-30
US20090170890A1 (en) 2009-07-02
WO2009055524A8 (en) 2010-08-26
EP2207801A1 (en) 2010-07-21
EP2207801B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
AP1639A (en) Pharmaceutical compositions of antiviral compounds and processes for preparation.
NZ584686A (en) Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
EP1834637A4 (en) COMPOSITION FOR THE PREVENTION / TREATMENT OF DISEASES THROUGH FREE RADICALS
TNSN06076A1 (en) Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
TW200630093A (en) Dose forms
JP2010174019A5 (es)
WO2008082601A3 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
MX2007011174A (es) Metodos y formulaciones de metformina para tratar constipacion cronica.
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
JP2010513229A5 (es)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
MX2010003923A (es) Formulacion farmaceutica de valsartan.
MA31598B1 (fr) Composes antiviraux, compositions et leurs procedes d'utilisation
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
JP2014526541A5 (es)
HK1127964A1 (en) Therapeutic agent for inflammatory bowel disease
WO2007092469A3 (en) Combination of organic compounds
MX2010004361A (es) Metodos para inhibir infeccion viral.
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007145863A3 (en) Sustained release formulation of naltrexone
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
WO2009027482A3 (en) Tsh receptor antagonizing tetrahydroquinoline compounds